Engineered disulfide-forming amino acid substitutions interfere with a conformational change in the mismatch recognition complex Msh2-Msh6 required for mismatch repair*

Victoria V. Hargreaves, Christopher D. Putnam, and Richard D. Kolodner

Ludwig Institute for Cancer Research, Departments of Medicine and Cellular and Molecular Medicine and Cancer Center, Moores-UCSD Cancer Center, and Institute of Genomic Medicine, University of California School of Medicine, San Diego 9500 Gilman Drive, La Jolla, CA 92093-0669

*Running title: Mismatch repair requires an Msh6 conformational change.

To whom correspondence should be addressed: Richard D. Kolodner, rkolodner@ucsd.edu, (858) 534-7804 (phone) (858) 534-7750 (fax)

Keywords: Engineered disulfide bond, DNA mismatch repair, conformational change

Background: The mismatch recognition complex Msh2-Msh6 undergoes an ATP-mediated conformational change.

Results: An engineered disulfide bond inhibits the conformational change and ATP-induced formation of the mispair-dependent Msh2-Msh6 sliding clamp and Msh2-Msh6-Mlh1-Pms1 ternary complexes.

Conclusion: The conformational change is required for mismatch repair.

Significance: This is the first direct test for the requirement of the Msh2-Msh6 conformational change in mismatch repair.

SUMMARY

ATP binding causes mispair-bound Msh2-Msh6 mismatch recognition complex to slide along the DNA away from the mismatch, and ATP is required for the mispair-dependent interaction between Msh2-Msh6 and Mlh1-Pms1. It has been inferred from these observations that ATP induces conformational changes in Msh2-Msh6; however, the nature of these conformational changes and their requirement in mismatch repair are poorly understood. Here we show that ATP induces a conformational change within the C-terminal region of Msh6 that protects the trypsin cleavage site after Msh6 residue R1124. An engineered disulfide bond within this region prevented the ATP-driven conformational change and resulted in an Msh2-Msh6 complex that bound mispaired bases but could not form sliding clamps or bind Mlh1-Pms1. The engineered disulfide bond also reduced mismatch repair efficiency in vivo, indicating that this ATP-driven conformational change plays a role in mismatch repair.

Mismatch repair (MMR) identifies and repairs mispaired bases that occur in DNA as the result of errors during DNA replication, the formation of recombination intermediates, or chemical damage to DNA (1-5). As MMR normally functions to suppress the accumulation of mutations, defects in MMR genes underlie both inherited and spontaneous cancers that are driven by high rates of accumulating mutations (6-9). In E. coli, the MutS homodimer recognizes mispairs (2,3,10-13), while in S. cerevisiae and humans, one of two heterodimers of MutS homologs, Msh2-Msh3 or Msh2-Msh6, recognizes mispairs (4,14-17). Mispair recognition by the MutS family of proteins is the first step of MMR that leads to the recruitment of either the bacterial MutL homodimer or the eukaryotic MutL homolog heterodimers, Mlh1-Pms1 or Mlh1-Mlh3, to mediate downstream steps, which lead to excision and resynthesis of the DNA strand that contained the misincorporated bases (18-26).

MutS and its homologs contain ABC ATPase domains, and multiple lines of
evidence indicate that ATP plays crucial roles in the function of these proteins (27-36). In the absence of nucleotide or the presence of ADP, these complexes can recognize mispairs; however, these pre-bound complexes form “sliding clamps” that dissociate from the mispair and slide along the DNA when challenged with ATP or non-hydrolyzable ATP analogs (18,19,28,30). These sliding clamps can be trapped on DNA fragments with sterically blocked ends (18,19,24,30,37). ATP binding by MutS and its homologs is also required for the ability of these proteins to interact with MutL or the eukaryotic MutL homologs, respectively, and thereby mediate downstream events in MMR (18-20,24). Together these biochemical results are consistent with the presence of an ATP-induced conformational change in MutS, Msh2-Msh3, and Msh2-Msh6 that propagates from the ATPase domain to other parts of the molecule.

To date, the details of ATP-driven conformational changes in MutS, Msh2-Msh3, and Msh2-Msh6 have proven elusive (38). Crystal structures of bacterial MutS, human Msh2-Msh3, and Msh2-Msh6 bound to mispairs have been solved and have provided important details of the ADP- and mispair-bound states of these proteins (2,10,39,40). This state has been called the open form (41), (42). In contrast, the conformation of the ATP-bound forms of these proteins is unknown. Based on structural homology to ATP-bound Rad50 (43), this form of the MutS family of proteins has been called the closed form (41,42). Consistent with these inferred states, deuterium exchange studies with S. cerevisiae Msh2-Msh6 demonstrated that ATP binding protects the Msh2-Msh6 dimer interface between the ATPase domains and exposes the mispair-binding domains (42). ATP binding moderately increases deuterium exchange in the connector domains of MutS and Msh2 (42), which interact with MutL or Mlh1-Pms1 respectively (44,45). These data are consistent with a model in which ATP binding releases the mispair binding domain from the mispair and exposes the connector domain to recruit MutL/Mlh1-Pms1. However, the details of and the requirement for these conformational changes in MMR remain poorly characterized. In the studies presented here, we have used a combination of genetic and biochemical approaches to identify a region undergoing an ATP-induced conformational change and demonstrate its functional involvement in MMR.

EXPERIMENTAL PROCEDURES

Strains, Plasmids, and Genetic Manipulations
S. cerevisiae strains were grown in standard medium, including either yeast extract/peptone/dextrose or complete supplement mixture medium (United States Biological) lacking specific amino acids to select for plasmid markers and/or Thr* revertants. Escherichia coli strains used for the propagation of plasmids were grown in LB medium containing 100 µg/mL ampicillin to select for plasmids. All S. cerevisiae strains used for genetic tests were isogenic derivatives of the same parental S288C strain (46). The strain used for the complementation studies was RDKY4234 (MATα ura3-52 leu2Δ1 trp1Δ63 his3Δ200 hom3-10 lys2::InsE-A10 msh3Δ::hisG msh6Δ::hisG). Plasmid pRDK439 was from our laboratory collection and was constructed by cloning a 6 kb fragment of S. cerevisiae genomic DNA containing MSH6 into the ARS CEN vector pRS315. The dual Msh2-Msh6 E. coli expression plasmid pET11a-Msh2-Msh6 was from Dr. Manju Hingorani (47). Derivatives of pRDK439 and pET11a-Msh2-Msh6 containing the indicated MSH6 alleles were made by site-directed mutagenesis and were verified by sequencing the complete MSH6 gene (Table 1). The msh6 truncation alleles 1125stop, 1135stop, 1152stop, 1172stop, 1182stop, 1191stop, 1201stop, 1211stop, 1221stop, and 1241stop were engineered by inserting two stop codons at the indicated position. The msh6 truncation alleles 1231 stop and 1236 stop were engineered by deleting codons 1231-1242 and 1236-1242, respectively. All of the genetic methods used in the described studies, including those used for site-directed mutagenesis, verification by DNA sequencing, and evaluation of mutator phenotypes by patch tests and fluctuation
analysis, were as described previously (15,35,48,49).

**Proteins** - Wild-type and mutant Msh2-Msh6 complexes were purified from *E. coli* as described (24,47,49,50). Wild-type Msh2-Msh6 and Msh2-Msh6 L1129C S1137C were purified in buffer A (25 mM Tris pH 8.0, 314 mM NaCl, 1mM EDTA, 10% glycerol, 5 mM DTT, 0.02% Igepal, 1mM phenylmethylsulfonyl fluoride (PMSF), 1mM benzamidine, 0.5 mg/liter bestatin, and 1 mg/liter each of chymostatin, pepstatin A, aprotinin, and leupeptin). Reduced wild-type Msh2-Msh6 and reduced Msh2-Msh6 L1129C S1137C were purified in buffer A (25 mM Tris pH 8.0, 314 mM NaCl, 1mM EDTA, 10% glycerol, 5 mM DTT, 0.02% Igepal, 1mM phenylmethylsulfonyl fluoride (PMSF), 1mM benzamidine, 0.5 mg/liter bestatin, and 1 mg/liter each of chymostatin, pepstatin A, aprotinin, and leupeptin). Reduced wild-type Msh2-Msh6 and reduced Msh2-Msh6 L1129C S1137C were maintained in buffer A. Wild-type Msh2-Msh6 and Msh2-Msh6 L1129C S1137C were oxidized by overnight dialysis at 4°C against buffer A lacking DTT. ATP-supplemented oxidized Msh2-Msh6 L1129C S1137C was generated by overnight dialysis at 4°C against buffer A lacking DTT and containing 100 µM ATP in the absence of Mg²⁺. Mlh1-Pms1 was purified from *S. cerevisiae* as described (24,41). LacI protein was generously provided by Kathleen Matthews (Rice University).

**Mass spectrometry** - To determine which region of Msh6 was undergoing the ATPγS-induced conformational change, approximately 300 ng each of full-length Msh6 and the 90, 80, and 75 kDa Msh6 tryptic fragments were separated by SDS-PAGE on a 4-15% gradient gel. After staining and destaining, the gel was incubated in water overnight, and the bands of interest were each excised from the gel with a clean razor blade. In gel slice reduction, alkylation, and trypsin digestion was performed by the Proteomics Mass Spectrometry Laboratory at the Scripps Research Institute, La Jolla, California. Briefly, the proteins were reduced in 10 mM DTT (Sigma) for one hr, then alkylated with 55 mM iodoacetamide (Sigma) for 30 minutes in the dark, and finally digested for 18 hrs with trypsin at 37°C using a 1:30 (w/w) enzyme to substrate ratio. The digestion reaction was stopped by lowering the pH of the reaction to 2.0. Tryptic peptides were analyzed by reverse phase chromatography using Zorbax SB-C18 stationary phase (Agilent). The data-dependent MS/MS data were obtained on a LTQ linear ion trap mass spectrometer (Thermo Scientific). Protein identification was performed using Mascot (Matrix Science, version 2.1.04). Tandem mass spectra were extracted by the Xcalibur software, and all MS/MS samples were analyzed using Mascot. Scaffold (Proteome Software Inc.) was used to additionally validate MS/MS-based peptide and protein identifications.

To demonstrate the presence of the disulfide bond, 20 µg of oxidized and reduced Msh2-Msh6 L1129C S1137C were each treated with 2% iodoethanol (Sigma) for one hr at 37°C in the dark. The protein was then precipitated by addition of a mixture of 50% ethanol, 50% acetonitrile containing 0.1% acetic acid for one hr on ice. Then the proteins were denatured with 8 M urea, reduced with 10 mM DTT for 10 min at 42°C, alkylated with 30 mM iodoacetamide (Sigma) for 30 min at room temperature in the dark, digested with 0.2 µg sequencing grade trypsin (Promega) at 37°C overnight, and the digestion reaction was stopped with 0.2% trifluoroacetic acid. Peptide cleanup was then performed using a 50 mg Sep-pak C18 column (Waters) that had been equilibrated with 0.1% acetic acid. Bound peptides were eluted from the column with 300 µl of 80% acetonitrile, 0.1% acetic acid; the eluate was lyophilized; and the resulting peptides were resuspended in 0.1% trifluoroacetic acid. The samples were then analyzed by LC-MS/MS using an LTQ Orbitrap Discovery XL mass spectrometer (Thermo Scientific). Data-dependent MS/MS data collected were searched using Sorcerer™-SEQUEST (51) with a semi-tryptic modified database designed for the mutant Msh6. Variable modifications for cysteine were applied for carbamidomethyl (+57 Da) and ethanol (+44 Da) with a peptide mass tolerance of 20 ppm. MS/MS peptide modification and protein identification were additionally validated by manual inspection.

**Partial proteolysis** - To monitor the ATPγS-induced conformational change in Msh2-Msh6, 4 µg of wild-type Msh2-Msh6 or Msh2-Msh6 L1129C S1137C was incubated...
with 0-500 ng trypsin with or without 100 μM ATPγS in reaction buffer (25 mM Tris, pH 8.0, 110 mM NaCl, 4 mM MgCl2, 0.01% IGEPA, 2 mM dithiothreitol, 2% glycerol) in a final volume of 10 μl for one hr at room temperature (23°C). Reactions were stopped by the addition of PMSF to a final concentration of 10 mM. The proteolysis products were separated by SDS-PAGE on a 4-15% gel (Bio-Rad), and the resulting gel was silver-stained.

Surface plasmon resonance - Experiments analyzing the interaction between the Msh2-Msh6 complex and mispaired DNA as well as the formation of the Msh2-Msh6-Mlh1-Pms1 ternary complex on mispaired DNA were performed with a Biacore T100 instrument (GE Healthcare) essentially as described previously (41,44). Note that the buffers used in these experiments contained Mg2+.

UV Cross-linking - Nucleotide binding was measured by UV cross-linking essentially as described previously (28). Briefly, 20 μl reactions containing 10 pmol reduced wild-type Msh2-Msh6, 30 pmol oxidized wild-type Msh2-Msh6, 30 pmol reduced Msh2-Msh6 L1129C S1137C, 50 pmol oxidized Msh2-Msh6 L1129C S1137C, or 50 pmol oxidized Msh2-Msh6 L1129C S1137C that had been dialyzed overnight against buffer containing ATP without Mg2+, were each performed in binding buffer that contained 50 mM Tris pH 8.0, 110 mM NaCl, 100 μg/ml BSA, 0.5 mM EDTA, 5% glycerol. The reactions with reduced protein also contained 2 mM dithiothreitol. The absence of magnesium prevented ATP hydrolysis. Proteins were mixed with 25 μCi/mmol γ-32P ATP and incubated on ice for 10 min. Samples were then subjected to UV-crosslinking (Stratalinker) for 20 min followed immediately by fractionation by SDS-PAGE using 4-15% gradient gels. The gels were exposed to a PhosphoImager screen overnight, and the screen was developed using a PhosphorImager (Molecular Dynamics).

RESULTS

ATP binding to Msh2-Msh6 protects the C-terminus of Msh6 from trypsin cleavage - We previously demonstrated that ATP binding protected Msh2-Msh6 from digestion with trypsin (Fig.1A), consistent with a conformational change (41). To determine which part of Msh2-Msh6 undergoes the ATP-induced conformational change, bands corresponding to full-length Msh6 and the 90 kDa, 80 kDa, and 75 kDa trypsin fragments were excised from a gel, digested to completion with trypsin, and analyzed by mass spectrometry (MS; Fig.1B-E). Consistent with Western blots (41), MS confirmed that the 90 kDa, 80 kDa, and 75 kDa trypsin fragments were derived from Msh6.

The 90 kDa, 80 kDa, and 75 kDa fragments yielded the same pattern and proportions of N-terminal tryptic peptides, and therefore appeared to have the same N-terminus. For each trypsin fragment, MS failed to detect significant amounts of any peptides N-terminal to the trypsin cleavage site at R441-E442 (Fig.1C-E), unlike full-length Msh6 from which substantial amounts of peptides starting with the first residue were detected (Fig.1B). This suggests that the N-terminus of the 90 kDa, 80 kDa, and 75 kDa fragments was residue E442. Residue E442 lies in the N-terminus of the connector domain of Msh6, C-terminal to a loop connecting the connector domain with the mispair-binding domain and appears to be exposed. Thus, the 90 kDa, 80 kDa, and 75 kDa fragments lack the mispair binding domain and the N-terminal tether that contains the PCNA interaction site (Fig.1C-E).

MS analysis indicated the 90 kDa, 80 kDa, and 75 kDa fragments had different C-termini, which were consistent with their molecular weights estimated by SDS PAGE. As for intact Msh6, significant amounts of peptides from the 90 kDa fragment sample were observed up to and including the C-terminal peptide ending in residue S1242 (Fig.1C). An Msh6 E442-S1242 fragment has a calculated molecular weight of 90.4 kDa, consistent with the estimated size of the fragment analyzed. In contrast, the 80 kDa fragment had reduced levels of tryptic peptides between residues R1171 and S1242 (Fig.1D). Residue R1171 is in the last alpha
helix of the ATPase domain of Msh6, as predicted by homology to the human Msh2-Msh6 structure (Fig.1F-G), and an Msh6 E442-R1171 fragment has a calculated molecular weight of 82.7 kDa, consistent with the estimated size of the fragment analyzed. MS analysis of the 75 kDa fragment was indicative of an even smaller fragment; significant levels of tryptic peptides were not identified C-terminal to residue R1124 (Fig.1E). Residue R1124 is between the last two beta strands of the ATPase domain, as predicted by homology to the human Msh2-Msh6 structure (Fig.1F-G), and an Msh6 E442-R1124 fragment has a calculated molecular weight of 77.5 kDa, consistent with the estimated size of the fragment analyzed. These results support the idea that ATP binding induces a conformational change in the region containing Msh6 residue R1124, which protects the R1124-N1125 trypsin site from cleavage.

The C-terminus of Msh6 is required for MMR - To determine if the C-terminal region of Msh6 that is affected by ATP binding is required for MMR, we constructed a series of MSH6 deletions that eliminated amino acids from the C-terminus of Msh6. These mutant genes were expressed on low copy-number plasmids and tested for their ability to complement the high frameshift mutation rate of an msh3Δ msh6Δ strain. The mutant lacking the last two codons of MSH6 (1241stop) fully complemented the high frameshift mutation rate of an msh3Δ msh6Δ strain in patch tests, like a wild-type MSH6 plasmid (Fig.2A), and had a similar mutation rate to that of the wild-type MSH6 plasmid in quantitative mutation rate tests (Table 2). The mutant lacking the last seven codons of MSH6 (1236stop) had an intermediate mutation rate, which was eight-fold higher than seen with the wild-type MSH6 plasmid (Table 2). In contrast, deletion of 12 or more amino acids from the C-terminus (1125stop to 1231stop) resulted in plasmids that failed to complement the high frameshift mutation rate of an msh3Δ msh6Δ strain in patch tests, like the empty vector control plasmid (Fig.2A). The strains containing plasmids with stop codons at 1221 and 1231 had mutation rates that were 199- and 149-fold higher, respectively, than that obtained with a plasmid containing wild-type MSH6, and were similar to the rates obtained with the empty vector control plasmid (Table 2). These results indicate that virtually the entire C-terminal region of Msh6 is required for MMR, including regions not ordered in the human Msh2-Msh6 structure (Fig.2B; (39)), and would be consistent with a C-terminal Msh2-Msh6 dimerization domain equivalent to the human Msh2-Msh3 C-terminal domain (40).

An engineered disulfide bond in the C-terminus of Msh6 disrupts MMR - We next analyzed the C-terminal region of Msh6 near the ATP-protected R1124-N1125 trypsin site for residues that could be changed to cysteines that would then have the potential to generate a disulfide bond under oxidizing conditions. Residues 1129 and 1137 are in close proximity and are in a region undergoing ATP-induced changes (42), but they are not ideally positioned for disulfide bond formation in the crystal structure of human Msh2-Msh6 (39). We reasoned that if conformational changes allowed for disulfide bond formation in the mutant protein, then disulfide bond formation might in turn affect conformational changes in Msh2-Msh6.

We then created single and double cysteine mutations in a plasmid-encoded MSH6 gene and tested for their effect on MMR (Fig.3A). The msh6-L1129C and msh6-S1137C mutations individually appeared to be weak mutator mutations in patch tests as did alternative mutations affecting these residues including msh6-L1129D and msh6-S1137A. In contrast, the msh6-L1129C S1137C pair of mutations, which we predicted to form a disulfide bond, caused a significantly stronger mutator phenotype in patch tests, unlike the msh6-L1129D S1137A pair. Other potential cysteine pairs in this region were investigated but not studied further as the other double cysteine mutants did not have increased mutation rates over the single cysteine mutants. Quantitative mutation rate tests confirmed that the msh6-L1129C S1137C allele caused a significant increase in mutation rate although not as large as a complete...
deletion of MSH6 (Table 2). In contrast, the mutation rates caused by the msh6-L1129C and msh6-S1137C mutations were not significantly different from the wild-type mutation rate (Table 2). Thus, the MMR defect occurred only in the double cysteine mutant.

To demonstrate the formation of a disulfide bond, Msh2-Msh6 L1129C S1137C was overexpressed and purified. An oxidized sample was generated by overnight dialysis against buffer A lacking DTT to enable any potential disulfide bonds to form. Both oxidized and reduced Msh2-Msh6 L1129C S1137C were treated with iodoethanol, denatured, reduced, and treated with iodoacetamide. In this experiment, exposed cysteines not in disulfide bonds will react with iodoethanol to become 2-hydroxyethyl-modified and have a total mass of 147 Da. Cysteines in disulfide bonds or buried within the protein will react with iodoacetamide after denaturation and reduction to become carbamidomethyl-modified and have a total mass of 160 Da (Fig.4A). Thus, exposed cysteines in disulfide bonds should be 2-hydroxyethyl-modified in the reduced sample and carbamidomethyl-modified in the oxidized sample. In contrast, cysteines not in disulfide bonds should be either 2-hydroxyethyl-modified if they are exposed or carbamidomethyl-modified if they are buried regardless of whether the sample is oxidized or reduced.

After this treatment, S1137C was observed as carbamidomethyl-modified 73% of the time in the oxidized sample and 31% in the reduced sample (Fig.4B). L1129C was not observed in the oxidized sample and was only observed once in the reduced sample. L1129C may not have been detected for a variety of technical reasons including vaporization and/or time of flight. Thus no significant conclusions can be drawn about L1129C. However, it should be noted that this analysis method allows inference of disulfide bond status even when both cysteine-containing peptides are not recovered as disulfide formation is detected through analysis of the properties of the modified cysteines. Eleven additional Msh6 cysteines were observed more than once in both the oxidized and reduced samples (Fig.4C), but only the modification of S1137C was significantly affected by the presence of DTT (p=0.003; Fisher’s exact test). Thus, at least 73% of S1137C in oxidized Msh2-Msh6 L1129C S1137C was disulfide bonded. Possible explanations for the observation of 27% 2-hydroxyethyl-modified S1137C are incomplete disulfide bond formation due to protein dynamics in this region of the protein or that dialysis treatment was insufficient to oxidize 100% of the cysteine residues.

**Oxidized Msh6 L1129C S1137C prevents ATP-induced conformational changes** - To determine how the engineered disulfide bond affected the ATP-induced Msh2-Msh6 conformational change, we repeated the partial proteolysis analysis using reduced and oxidized Msh2-Msh6 L1129C S1137C. As for both reduced and oxidized wild-type Msh2-Msh6, ATPγS prevented trypsin from cleaving the reduced Msh6 L1129C S1137C into the 75 kDa fragment (Fig.5). In contrast, trypsin generated the 75 kDa fragment from oxidized Msh2-Msh6 L1129C S1137C regardless of whether or not ATPγS was present, consistent with the possibility that disulfide bond formation trapped Msh2-Msh6 L1129C S1137C in the ATP-unbound conformation. When the oxidized Msh2-Msh6 L1129C S1137C was dialyzed overnight against buffer lacking both DTT and Mg^{2+} and containing 100 µM ATP at 4°C, trypsin digestion was unable to generate the 75 kDa fragment, regardless of whether or not ATPγS was in the proteolysis reaction (Fig.5), consistent with slow binding of ATP and subsequent conformational changes during dialysis. Together, these results suggest that oxidized Msh2-Msh6 L1129C S1137C can bind ATP and undergo ATP-driven conformational changes but on an extremely slow time scale.

**Oxidized Msh2-Msh6 L1129C S1137C binds mispaired bases but is defective for sliding clamp formation** - Wild-type Msh2-Msh6 in either the nucleotide free or ADP-bound state can bind to mispairs. Challenging these complexes with ATP converts wild-type
Msh2-Msh6 to a sliding clamp that slides away from the mispair along the DNA (28). Sliding clamp formation by Msh2-Msh6 can be monitored by surface plasmon resonance by following the accumulation of multiple Msh2-Msh6 molecules on an immobilized DNA molecule containing a single mispair under conditions in which the DNA ends are blocked (24). To do this, a 236-base pair oligonucleotide with a central GT mispair, a biotin at one end, and a lac operator sequence at the other end was bound to a streptavidin-coated Biacore chip at its biotinylated end. Addition of LacI, which binds the lac operator and can be removed by addition of IPTG, sterically blocks the DNA end and prevents Msh2-Msh6 from sliding off of the DNA.

Both oxidized and reduced wild-type Msh2-Msh6 bound mispaired DNA in the presence of ATP and Mg2+ (red dashed line, Fig.6A,C). Under these conditions, free Msh2-Msh6 hydrolyzes ATP to yield the ADP-bound state in which it binds the mispair, exchanges ADP for ATP, and then slides off the DNA end, resulting in the steady state level of binding seen (24). Addition of LacI increases the number of molecules bound to the DNA substrate (red solid line, Fig.6), and release of LacI with IPTG returns binding back to the steady-state level (green solid line, Fig.6). This pattern of LacI-dependent accumulation of Msh2-Msh6 on the DNA substrate demonstrated that both oxidized and reduced wild-type Msh2-Msh6 can form sliding clamps (24). Reduced Msh2-Msh6 L1129C S1137C had the same binding properties as wild-type Msh2-Msh6, indicating that the mutant can form sliding clamps under reduced conditions (Fig.6B). In contrast, oxidized Msh2-Msh6 L1129C S1137C (Fig.6D) and oxidized Msh2-Msh6 L1129C S1137C that had been dialyzed overnight against buffer containing ATP (Fig.8E) did not support the binding of Mlh1-Pms1 (Fig.8B). In contrast, oxidized Msh2-Msh6 L1129C S1137C (Fig.8D) and oxidized Msh2-Msh6 L1129C S1137C that had been dialyzed overnight against buffer containing ATP (Fig.8E) did not support the binding of Mlh1-Pms1. These results suggest that the ability of the Msh6 C-terminal region to switch between the two conformations is required for interaction between Msh2-Msh6 and Mlh1-Pms1.

Oxidized Msh2-Msh6 L1129C S1137C has a low affinity for ATP - We previously demonstrated that ATP binding to both the Msh2 and Msh6 subunits as well as communication between the subunits is required for sliding clamp formation, and that ATP binding to only the Msh6 subunit is required for ternary complex formation (41). We used ATP cross-linking to determine if the inability of oxidized Msh2-Msh6 L1129C S1137C to form sliding clamps or ternary complexes with Mlh1-Pms1 might result from a reduced affinity for ATP. The absence of...
Mg$^{2+}$ in the cross-linking reaction buffer prevented ATP hydrolysis but could have had a minor influence on the nucleotide binding characteristics of Msh2-Msh6 (28,52). Reduced and oxidized wild-type Msh2-Msh6 had similar affinities for ATP. Consistent with the results of previous studies (28), 50% saturation of ATP ($S_{0.5}$) in wild-type Msh6 for ATP was achieved at concentrations below 1 µM, and the $S_{0.5}$ of Msh2 for ATP was between 20 and 50 µM (Fig.9). In reduced Msh2-Msh6 L1129C S1137C, the $S_{0.5}$ of Msh2 and Msh6 for ATP were similar to each other and were between 20 and 50 µM, similar to the affinity of Msh2 for ATP in wild-type Msh2-Msh6. This indicates that in reduced Msh2-Msh6 L1129C S1137C, the Msh6 subunit has a lower affinity for ATP relative to that in wild-type Msh2-Msh6; however, reduced Msh2-Msh6 L1129C S1137C is likely proficient for sliding clamp formation and the formation of ternary complexes because the assays for these features were performed in buffer containing 250 µM ATP, a concentration significantly higher than the $S_{0.5}$ for ATP binding to each subunit.

In contrast, the affinities of both Msh2 and Msh6 for ATP were significantly reduced in oxidized Msh2-Msh6 L1129C S1137C, with the $S_{0.5}$ for ATP for both Msh2 and Msh6 being between 50 and 250 µM (Fig.9). This result supports the possibility that the inability of oxidized mispair-bound Msh2-Msh6 L1129C S1137C to form either sliding clamps or ternary complexes with Mlh1-Pms1 is due to the drastically reduced affinities of both the Msh2 and Msh6 subunits for ATP. Interestingly, both subunits, particularly Msh6 L1129C S1137C, of the oxidized Msh2-Msh6 double mutant, which had been diazylated in ATP overnight in the absence of Mg$^{2+}$ and had undergone the ATP-induced conformational change as evidenced by the partial proteolysis pattern (Fig.5), had even weaker affinities for ATP than those of oxidized Msh2-Msh6 L1129C S1137C. This is most likely due to stable binding of unlabeled ATP, which forced the mutant to undergo the conformational change, competing with the radioactively labeled ATP in the crosslinking reaction. The severely reduced affinity of ATP-supplemented oxidized Msh2-Msh6 L1129C S1137C for ATP is consistent with its inability to form the sliding clamp or ternary complex.

**DISCUSSION**

The Msh2-Msh6 complex appears to exist in at least two biochemically distinct forms that are modulated by ATP binding and hydrolysis. The nucleotide free and ADP bound forms are proficient for mispair binding (19,28). ATP binding prevents Msh2-Msh6 from binding mispairs, but converts the mispair bound form to a sliding clamp and a form that recruits Mlh1-Pms1 (18-20,24,28,41). These changes in biochemical properties are also mirrored by changes in partial proteolysis (36,41) and are consistent with results from electron microscopy (30), deuterium exchange (42), analytical ultracentrifugation (38), and single-molecule FRET (53). Despite this, the requirement for conformational changes in the MutS family of proteins during MMR is not well understood (30,38,41,42). To understand the role this conformational change plays in the activities of Msh2-Msh6 and MMR, we sought to introduce a reversible disulfide crosslink to prevent Msh2-Msh6 from transitioning between states.

To model the effects of ATP binding on the ATPase domains of Msh2-Msh6, we compared the DNA-bound structures of MutS, Msh2-Msh6, and Msh2-Msh3, which are considered to be the open form of the ABC ATPases (2,10,39,40,54,55), with the ATP-bound form of Rad50, which is considered to be the closed form of the ABC ATPases (43). This analysis indicated that the ATPase domains could readily switch between an open ATP-free conformation and a closed ATP-bound conformation, except for the final two ordered helices of both Msh2 and Msh6 in the DNA co-crystal structure (39). These helix pairs most likely move relative to the rest of the ATPase domain (Fig.10A) due to steric collision with each other in the ATP-bound form as inferred from simple superposition of Msh2 and Msh6 onto Rad50 (Fig.10A) or potentially by rigid separation of these helix pairs by a C-terminal dimerization domain.
equivalent to that of *E. coli* MutS (56) or human Msh2-Msh3 (40) that is disordered in the human Msh2-Msh6 crystal structure (39). The existence of this dimerization domain in *S. cerevisiae* Msh2-Msh6 and its requirement in MMR, as with *Thermus aquaticus* and *E. coli* MutS (56,57), would explain why all of the Msh6 C-terminal residues, except for the last seven, are required for MMR (Fig.2A).

Conservation of this domain across MutS family members may be required to stabilize dimers so that the interface between the ATPase domains can change dynamically upon ATP binding. Regardless of the cause, movement of the final ordered helices of Msh2-Msh6 relative to the rest of the ATPase domain would move the loop containing Msh6 residues L1129 and S1137, and is consistent with ATP binding causing increased protection from deuterium exchange (Fig. 11) (42) and protection of the R1124-N1125 trypsin site from cleavage (Fig.1).

Introduction of double cysteine amino acid substitutions, L1129C and S1137C, into the loop of Msh6 preceding the final ordered helices generated a protein that formed a disulfide crosslink upon oxidation (Fig.4). Genetically, the double cysteine mutation reduced MMR proficiency in vivo albeit not to the same extent as caused by deleting *MSH6* (Fig.3A, Table 2). One potential reason why an *MSH6* deletion causes a higher mutation rate is that the cytoplasm of *S. cerevisiae* is reducing (58) and hence disulfide bond formation may not go to completion in vivo. However, under reducing conditions in vitro, 31% of mutant protein contained a L1129C-S1137C disulfide bond (Fig.4). Taken together, this suggests that a sufficient fraction of protein containing the disulfide bond can form in vivo to produce the elevated mutation rate observed in vivo.

The reduced Msh2-Msh6 L1129C-S1137C behaved like wild-type in the accessibility of the R1124-N1125 trypsin site in the open and closed conformations (Fig.5,10D), the formation of the sliding clamp (Fig.6), and recruitment of Mlh1-Pms1 (Fig.8). The greatest difference between the reduced mutant and wild-type proteins was the mutant Msh6 had a reduced affinity for ATP, which was equivalent to Msh2 in wild-type Msh2-Msh6 and Msh2-Msh6 L1129C-S1137C. Sliding clamp formation and recruitment of Mlh1-Pms1 differ in their ATP requirements in that recruitment of Mlh1-Pms1 only requires ATP binding to the high affinity Msh6 site, whereas sliding clamp formation requires ATP binding to both the Msh2 and Msh6 sites (41); however, the concentration of ATP in the experiment, 250 µM, was sufficient to saturate the ATP binding sites of the Msh2 and Msh6 subunits in this mutant explaining how it can be proficient for sliding clamp formation and recruitment of Mlh1-Pms1. This contrasts with other mutants, such as Msh2-R730C-Msh6 and Msh2-Msh6-R1024C, which were unable to form sliding clamps or bind Mlh1-Pms1 even when the ATP concentration was above the measured S0.5s for each subunit; Msh2-R730C-Msh6 and Msh2-Msh6-R1024C most likely have additional defects in communication between the ATP-binding sites (41).

The oxidized Msh2-Msh6 L1129C-S1137C, however, appeared to be defective for normal rapid rates of ATP binding as evidenced by the generation of the 75 kDa band in the presence of ATPγS (Fig.5,10E), its ability to bind mispairs (Fig.7), its failure to form a sliding clamp or recruit Mlh1-Pms1 (Fig.6,8), and its reduced affinity for ATP in both subunits (Fig.9). Although these effects can be attributed to lack of ATP binding by Msh6, the L1129C-S1137C disulfide bond is not at the nucleotide-binding site; it is located in a region undergoing ATP-induced changes according to deuterium exchange data (42). Thus, inhibition of rapid ATP binding is more likely due to disruption of ATP-induced conformational changes that generate the high affinity ATP-binding site, rather than disruption of the nucleotide-binding site per se. The fact that extensive dialysis of oxidized Msh2-Msh6 L1129C-S1137C against buffer containing ATP without Mg2+ converted it to a state in which trypsin was unable to generate the 75 kDa fragment (Fig.5,10F) is consistent with a slowed ATP-induced transition and is at odds with models in which the disulfide bond directly disrupts the nucleotide-binding site.
Thus, the formation of the disulfide bond appears to have generated an Msh2-Msh6 complex in which the ATP-induced conformational changes occur on the order of hours.

Supplementing oxidized Msh2-Msh6 L1129C S1137C with ATP reduced the affinity of both its subunits for ATP relative to oxidized Msh2-Msh6 L1129C S1137C. The unlabeled ATP from the dialysis most likely competed with the added labeled ATP in the UV-crosslinking experiment (Fig.9). The ATP-supplemented oxidized Msh6 L1129C S1137C subunit appeared to retain more unlabeled ATP than Msh2, resulting in less crosslinked labeled ATP. This result suggests that the C-terminal region of Msh6 affects ATP binding to Msh2, consistent with previous results (28,41,52). Interestingly, this ATP-bound form of oxidized Msh2-Msh6 L1129C S1137C was capable of binding mispaired bases (Fig.7), but did not form the sliding clamp or recruit Mlh1-Pms1 (Fig.6,8).

This is most likely because the bound ATP was hydrolyzed to ADP due to the presence of Mg^{2+} in the Biacore running buffer, which converted it to a mispair-binding proficient form (19,28), but the slow ATP binding prevented either sliding clamp formation or Mlh1-Pms1 binding.

The fact that in vitro oxidized Msh2-Msh6 L1129C S1137C is in the open conformation but can be slowly converted to the closed conformation (Fig.5,10) indicates that the disulfide bond slows ATP binding to Msh2 and Msh6, and hence the dynamic interconversion between the open and closed forms that would be predicted to occur during MMR. Therefore the C-terminal conformational change in Msh6 plays a role in ATP processing, specifically ATP hydrolysis or ADP exchange for ATP. This, in turn, disrupts the formation of both Msh2-Msh6 sliding clamps and ternary complexes between Msh2-Msh6 and Mlh1-Pms1 and results in an MMR defect.
REFERENCES


ACKNOWLEDGEMENTS

We thank Kathleen Matthews for the generous gift of LaCl protein. We thank Jason Liang and Huilin Zhou for their assistance in analyzing the disulfide bond formation by mass spectrometry.

FOOTNOTES

*This work was supported by NIH grants GM50006 and CA092584.
Table 1. Plasmids

<table>
<thead>
<tr>
<th>Plasmid name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pRDK439</td>
<td>pRS315-MSH6</td>
</tr>
<tr>
<td>pRDK1641</td>
<td>pRS315-msh6 1125stop</td>
</tr>
<tr>
<td>pRDK1642</td>
<td>pRS315-msh6 1135stop</td>
</tr>
<tr>
<td>pRDK1643</td>
<td>pRS315-msh6 1152stop</td>
</tr>
<tr>
<td>pRDK1644</td>
<td>pRS315-msh6 1172stop</td>
</tr>
<tr>
<td>pRDK1645</td>
<td>pRS315-msh6 1182stop</td>
</tr>
<tr>
<td>pRDK1646</td>
<td>pRS315-msh6 1191stop</td>
</tr>
<tr>
<td>pRDK1647</td>
<td>pRS315-msh6 1201stop</td>
</tr>
<tr>
<td>pRDK1648</td>
<td>pRS315-msh6 1211stop</td>
</tr>
<tr>
<td>pRDK1649</td>
<td>pRS315-msh6 1221stop</td>
</tr>
<tr>
<td>pRDK1650</td>
<td>pRS315-msh6 1231stop</td>
</tr>
<tr>
<td>pRDK1651</td>
<td>pRS315-msh6 1236stop</td>
</tr>
<tr>
<td>pRDK1652</td>
<td>pRS315-msh6 1241stop</td>
</tr>
<tr>
<td>pRDK1653</td>
<td>pRS315-msh6-L1129D</td>
</tr>
<tr>
<td>pRDK1654</td>
<td>pRS315-msh6-S1137A</td>
</tr>
<tr>
<td>pRDK1655</td>
<td>pRS315-msh6-L1129D S1137A</td>
</tr>
<tr>
<td>pRDK1656</td>
<td>pRS315-msh6-L1129C</td>
</tr>
<tr>
<td>pRDK1657</td>
<td>pRS315-msh6-S1137C</td>
</tr>
<tr>
<td>pRDK1658</td>
<td>pRS315-msh6-L1129C S1137C</td>
</tr>
<tr>
<td>pET11a-MSH2-MSH6</td>
<td>pET11a-MSH2-MSH6</td>
</tr>
<tr>
<td>pRDK1640</td>
<td>pET11a-MSH2-msh6-L1129C S1137C</td>
</tr>
<tr>
<td>pRDK573</td>
<td>pRS424-GAL-MLH1</td>
</tr>
<tr>
<td>pRDK1099</td>
<td>pRS425-GAL-PMS1-FLAG</td>
</tr>
</tbody>
</table>
Table 2. Mutation rate analysis of *msh6* mutants

<table>
<thead>
<tr>
<th>Relevant genotype</th>
<th>Mutation rate (fold increase)</th>
<th>Thr&lt;sup&gt;+&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>msh3Δ MSH6</em></td>
<td>3.72 [1.95-13.4] x 10&lt;sup&gt;-8&lt;/sup&gt; (1)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6Δ</em></td>
<td>4.96 [3.53-9.99] x 10&lt;sup&gt;-6&lt;/sup&gt; (133)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6 1221 stop</em></td>
<td>7.39 [3.58-13.8] x 10&lt;sup&gt;-6&lt;/sup&gt; (199)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6 1231 stop</em></td>
<td>5.55 [2.06-11.5] x 10&lt;sup&gt;-6&lt;/sup&gt; (149)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6 1236 stop</em></td>
<td>2.96 [0.96-7.41] x 10&lt;sup&gt;-7&lt;/sup&gt; (8.0)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6 1241 stop</em></td>
<td>2.60 [1.82-5.45] x 10&lt;sup&gt;-8&lt;/sup&gt; (0.7)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6-L1129C</em></td>
<td>9.73 [6.96-28.1] x 10&lt;sup&gt;-8&lt;/sup&gt; (2.6)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6-S1137C</em></td>
<td>4.67 [3.6-16.8] x 10&lt;sup&gt;-8&lt;/sup&gt; (1.3)</td>
<td></td>
</tr>
<tr>
<td><em>msh3Δ msh6-L1129C S1137C</em></td>
<td>3.16 [2.36-10.6] x 10&lt;sup&gt;-7&lt;/sup&gt; (8.5)</td>
<td></td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

FIGURE 1. Identification of the ATP-protected trypsin site in Msh6. (A) The addition of ATP to a partial proteolysis reaction with Msh2-Msh6 prevents the generation of the 75 kDa fragment as previously demonstrated (41). (B-E) Histograms of the number of times each amino acid was observed by mass spectrometry for (B) full-length Msh6 and the (C) 90, (D) 80, and (E) 75 kDa trypsin fragments. Labeled arrows indicate the predicted N- and C-termini for each trypsin fragment. (F) Ribbon diagrams of human Msh2-Msh6 and bound mispaired DNA (Msh2 red; Msh6 blue; DNA orange; PDB ID code 2O8B; (39)) and the same structure rotated 180° generated with PyMol (59). The positions of the N- and C-termini of the 90 kDa fragment (residues 442-1242), 80 kDa fragment (residues 442-1171), and 75 kDa fragment (residues 442-1124) are indicated with arrows to the equivalent residues in human Msh6. (G) Expanded view of Msh6 C-terminus with the C-termini of the 90, 80, and 75 kDa fragments indicated with arrows.

FIGURE 2. Msh6 residues 1124-1230 are required for MMR. (A) Patches of mshΔ mshΔ strains expressing plasmid-borne msh truncation alleles (Table 1) were replica plated onto plates lacking leucine and threonine to test for MMR complementation by suppression of hom3-10 reversion. The positions of the engineered stop codons are indicated. (B) A ribbon diagram of human Msh2-Msh6 with the C-terminus of Msh6 in black. The positions of the last codons in S. cerevisiae Msh6 are indicated with arrows (S. cerevisiae Msh6 residues 1171-1207 are missing from human Msh6 and the equivalent to S. cerevisiae Msh6 residue 1214 is the last ordered residue in the human Msh2-Msh6 structure).

FIGURE 3. msh2-msh6-L1129C S1137C causes an elevated mutation rate. (A) Patches of mshΔ mshΔ strains expressing plasmid-borne msh alleles (Table 1) were replica plated onto plates lacking leucine and threonine to test for MMR complementation by suppression of hom3-10 reversion. (B) Residues equivalent to S. cerevisiae Msh6 L1129 and S1137 are depicted by spheres on the ribbon diagram of human Msh2-Msh6 with the C-terminus of Msh6 in black.

FIGURE 4. Residues L1129C and S1137C form a disulfide bond in oxidized Msh2-Msh6 L1129C S1137C. (A) Schematic of the alkylation reactions. (B) Ratio of carbamidomethylation in the oxidized sample to carbamidomethylation in the reduced sample for Msh6 L1129C S1137C cysteines. The error bars indicate the standard deviation. (C) Residues equivalent to the cysteines in S. cerevisiae Msh6 are depicted by black spheres on the ribbon diagram human Msh2-Msh6.

FIGURE 5. Oxidized Msh2-Msh6 L1129C S1137C is trapped in the nucleotide-free conformation. Four µg of reduced or oxidized wild-type Msh2-Msh6 or reduced, oxidized, or ATP-supplemented oxidized Msh2-Msh6-L1129C S1137C were incubated with 50-200 ng trypsin with or without 100 µM ATPγS. The proteolysis products were separated by SDS-PAGE on a 4-15% gel, and the gel was silver-stained. Only the portion of the gels containing the 70-100 kDa size range is shown.

FIGURE 6. Msh2-Msh6 L1129C S1137C cannot form a sliding clamp under oxidizing conditions but can form a sliding clamp under reducing conditions. Approximately 20 ng of mispair-containing DNA was conjugated to a flow cell of a streptavidin-coated Biacore SA chip. In the unblocked sliding experiments, depicted by the red dashed line, 50 nM wild-type Msh2-Msh6 or Msh2-Msh6 L1129C S1137C and 250 µM ATP were flowed over the chip. In the end-
blocked sliding experiments, depicted by the red solid line, 30 nM LacI was flowed over the chip in reaction buffer before and during Msh2-Msh6 binding. Dissociation of Msh2-Msh6 from the DNA end was induced by the addition of 1 mM IPTG to the sample, which is depicted by the green solid line.

FIGURE 7. Oxidized Msh2-Msh6 L1129C S1137C prefers binding mispaired DNA to base-paired DNA. Binding of Msh2-Msh6 complexes to a 236 bp DNA containing a central GT mispair or GC base pair in the presence of 250 μM ATP was analyzed on a BIAcore T100 biosensor. The solid black line indicates association of the indicated Msh2-Msh6 complex with a fully base-paired DNA substrate. The solid red line indicates association with a DNA substrate containing a central GT mispair. All DNA substrates had LacI endblocks. (A) reduced wild-type Msh2-Msh6 (B) reduced Msh2-Msh6 L1129C S1137C (C) oxidized wild-type Msh2- Msh6 (D) oxidized Msh2-Msh6 L1129C S1137C (E) ATP-supplemented oxidized Msh2-Msh6 L1129C S1137C.

FIGURE 8. Msh2-Msh6 L1129C S1137C can form a ternary complex with Mlh1-Pms1 under reducing conditions but not oxidizing conditions. Approximately 20 ng of mispair-containing DNA was conjugated to a flow cell of a streptavidin-coated Biacore SA chip. The dashed lines depict experiments in which 20 nM wild-type or mutant Msh2-Msh6, 30 nM LacI, and 250 μM were flowed over the chip. In the plus Mlh1-Pms1 experiments, which are depicted by the red solid line, the injection contained 20 nM Msh2-Msh6, 40 nM Mlh1-Pms1, 30 nM LacI, and 250 μM ATP. The small contribution of Mlh1-Pms1 alone binding the mispaired DNA was subtracted from the plus Mlh1-Pms1 experiments.

FIGURE 9. Oxidized Msh2-Msh6 L1129C S1137C has a reduced affinity for ATP in both the Msh2 and Msh6 ATP-binding sites. Wild-type or mutant Msh2-Msh6 was incubated with γ-32P ATP, crosslinked, and fractionated by SDS-PAGE.

FIGURE 10. Model of the open to closed transition of Msh2-Msh6 caused by ATP binding. (A) Diagram of human Msh2-Msh6 with the two C-terminal alpha helices in ribbons and the rest of the protein in spheres and a representative cartoon. The ATP-bound conformation of human Msh2-Msh6 was modeled by individually superimposing the human Msh2 and Msh6 subunits (PDB ID code 2O8B) on the ATP-bound form of Pyrococcus furiosus Rad50 (PDB ID code 1F2U; (43)) using Sequoia (60). Views were chosen so that the Msh6 orientation is fixed. Cartoons of reduced wild-type Msh2-Msh6 (B), oxidized wild-type Msh2-Msh6 (C), reduced Msh2-Msh6 L1129C S1137C (D), oxidized Msh2-Msh6 L1129C S1137C (E), and ATP-supplemented oxidized Msh2-Msh6 L1129C S1137C (F).

FIGURE 11. Ribbon diagram of H. sapiens Msh2-Msh6 (PDB ID code 2O8B) with S. cerevisiae residues L1129C and S1137C and the R1124-N1125 trypsin cleavage site in spheres, ATP in sticks, residues protected from deuterium exchange by ATP binding depicted in purple, and residues unchanged upon ATP binding depicted in gray (42).
A. Msh2-Msh6
   trypsin
   90 kDa
   80 kDa
   75 kDa
Msh2-Msh6 + ATP
   trypsin
   90 kDa
   80 kDa

B. Full-length Msh6
   Amino acid residue position
   Times Observed
   500 1000
   0 100 200 300 400 500 1000

C. 90 kDa band
   Amino acid residue position
   Times Observed
   500 1000
   0 10 20 30 40

D. 80 kDa band
   Amino acid residue position
   Times Observed
   500 1000
   0 10 20 30 40

E. 75 kDa band
   Amino acid residue position
   Times Observed
   500 1000
   0 10 20 30 40

F. Figure 1

G. Msh6 Msh2
Figure 2

A. Vector MSH6-WT 1125stop 1135stop

msh3Δmsh6Δ

1152stop 1172stop 1182stop 1191stop Thr+

msh3Δmsh6Δ

1201stop 1211stop 1221stop Thr+

msh3Δmsh6Δ

1231stop 1236stop 1241stop Thr+

msh3Δmsh6Δ

1220, 1230, 1235, 1240

B. 1210 1181, 1190, 1200

1171

Msh6 Msh2

1134 1124 1151
Figure 3

A. Vector MSH6-WT msh6-L1129D msh6-S1137A msh6-L1129D S1137A msh6-L1129C S1137C msh3Δmsh6Δ msh6-L1129C S1137C msh3Δmsh6Δ Thr+

B. Msh6 Msh2 S1137 L1129

Downloaded from http://www.jbc.org/ by guest on July 15, 2017
Figure 4

A. Oxidized Msh2-Msh6 L1129C S1137C

\[
\begin{align*}
\text{Denature, reduce} & + \text{Iodoacetamide} \\
\text{S-S} & \rightarrow \text{S-S} \\
\text{SC}_2\text{H}_4\text{NO} & \rightarrow \text{SC}_2\text{H}_4\text{NO} \\
\text{carbamidomethyl modified} & \rightarrow \text{2-hydroxyethyl modified}
\end{align*}
\]

B. Graph showing the ratio of % carbamidomethyl modified oxidized : % carbamidomethyl modified reduced for Msh6 cysteine residues 3, 2, 1, 0.

C. Diagrams of Msh6 and Msh2.
Figure 5
Figure 6

Response units

WT Msh2-Msh6
red.

WT Msh2-Msh6
ox.

Msh2-Msh6
L1129C S1137C
red.

Msh2-Msh6
L1129C S1137C
ox. + ATP
Figure 7

- Panel A: WT Msh2-Msh6 red.
- Panel B: WT Msh2-Msh6 ox.
- Panel C: Msh2-Msh6 L1129C S1137C red.
- Panel D: Msh2-Msh6 L1129C S1137C ox.
- Panel E: Msh2-Msh6 L1129C S1137C ox. + ATP

The graphs illustrate the response units over time (in seconds) for different conditions.
Figure 8

A: WT Msh2-Msh6 red.

B: WT Msh2-Msh6 ox.

C: Msh2-Msh6 L1129C S1137C red.

D: Msh2-Msh6 L1129C S1137C ox.

E: Msh2-Msh6 L1129C S1137C ox. + ATP
Figure 9

![Figure 9: Western blots showing the protein expression levels of Msh6 and Msh2 in different conditions. The blots are divided into two sections: one for Msh6 and the other for Msh2. Each section contains sub-sections labeled 'reduced', 'oxidized', and 'oxidized + ATP'. The concentration of ATP in microM (µM) ranges from 1 to 250.](image-url)
Figure 11
Engineered disulfide-forming amino acid substitutions interfere with a conformational change in the mismatch recognition complex Msh2-Msh6 required for mismatch repair

Victoria V. Hargreaves, Christopher D. Putnam and Richard D. Kolodner

J. Biol. Chem. published online October 8, 2012 originally published online October 8, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.402495

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2012/10/12/jbc.M112.402495.full.html#ref-list-1